Publication: Prospective comparison of the AIMS65 score, glasgow-blatchford score, and rockall score for predicting clinical outcomes in patients with variceal and nonvariceal upper gastrointestinal bleeding
Issued Date
2021-03-01
Resource Type
ISSN
22342443
22342400
22342400
Other identifier(s)
2-s2.0-85104848667
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Endoscopy. Vol.54, No.2 (2021), 211-221
Suggested Citation
Arunchai Chang, Chokethawee Ouejiaraphant, Keerati Akarapatima, Attapon Rattanasupa, Varayu Prachayakul Prospective comparison of the AIMS65 score, glasgow-blatchford score, and rockall score for predicting clinical outcomes in patients with variceal and nonvariceal upper gastrointestinal bleeding. Clinical Endoscopy. Vol.54, No.2 (2021), 211-221. doi:10.5946/CE.2020.068 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78363
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prospective comparison of the AIMS65 score, glasgow-blatchford score, and rockall score for predicting clinical outcomes in patients with variceal and nonvariceal upper gastrointestinal bleeding
Other Contributor(s)
Abstract
Background/Aims: This study aimed to determine the performance of the AIMS65 score (AIMS65), Glasgow-Blatchford score (GBS), and Rockall score (RS) in predicting outcomes in patients with upper gastrointestinal bleeding (UGIB), and to compare the results between patients with nonvariceal UGIB (NVUGIB) and those with variceal UGIB (VUGIB). Methods: We conducted a prospective observational study between March 2016 and December 2017. Receiver operating characteristic curve analysis was performed for all outcomes for comparison. The associations of all three scores with mortality were evaluated using multivariate logistic regression analysis. Results: Of the total of 337 patients with UGIB, 267 patients (79.2%) had NVUGIB. AIMS65 was significantly associated (odds ratio [OR], 1.735; 95% confidence interval [CI], 1.148-2.620), RS was marginally associated (OR, 1.225; 95% CI, 0.973-1.543), but GBS was not associated (OR, 1.017; 95% CI, 0.890-1.163) with mortality risk in patients with UGIB. However, all three scores accurately predicted all other outcomes (all p<0.05) except rebleeding (p>0.05). Only AIMS65 precisely predicted mortality, the need for blood transfusion and the composite endpoint (all p<0.05) in patients with VUGIB. Conclusions: AIMS65 is superior to GBS and RS in predicting mortality in patients with UGIB, and also precisely predicts the need for blood transfusion and the composite endpoint in patients with VUGIB. No scoring system could satisfactorily predict rebleeding in all patients with UGIB.